{"id":92166,"date":"2024-12-10T15:43:08","date_gmt":"2024-12-10T18:43:08","guid":{"rendered":"https:\/\/murray.adv.br\/?p=92166"},"modified":"2024-12-10T15:43:11","modified_gmt":"2024-12-10T18:43:11","slug":"novo-nordisk-to-expand-enzyme-production-in-brazil","status":"publish","type":"post","link":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/","title":{"rendered":"Novo Nordisk to expand enzyme production in Brazil"},"content":{"rendered":"\n<h6 class=\"wp-block-heading has-text-align-center\"><em><strong>Expansion aims to boost production of enzymes essential for manufacturing Ozempic and Wegovy, medications used to treat diabetes and obesity<\/strong><\/em><\/h6>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p><\/p>\n\n\n\n<p>12\/10\/2024 <\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter is-resized\"><img decoding=\"async\" src=\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\" alt=\"Novo Nordisk\u2019s plant in Montes Claros: company\u2019s investment in Brazil over two years will reach R$1.3bn \u2014 Foto: Divulga\u00e7\u00e3o\" style=\"width:678px;height:auto\" \/><figcaption class=\"wp-element-caption\"><em>Novo Nordisk\u2019s plant in Montes Claros: company\u2019s investment in Brazil over two years will reach R$1.3bn \u2014 Photo: Divulga\u00e7\u00e3o<\/em><\/figcaption><\/figure>\n<\/div>\n\n\n<p>Danish pharmaceutical company Novo Nordisk announced on Monday (9) an additional investment of R$500 million in Brazil. The funds will be used to construct a new annex at the company\u2019s plant in Montes Claros, Minas Gerais. The expansion aims to boost the production of enzymes essential for manufacturing Ozempic and Wegovy, medications used to treat diabetes and obesity.<\/p>\n\n\n\n<p>With this investment, the total amount to be invested by the company in Brazil over the next two years will reach R$1.3 billion.<\/p>\n\n\n\n<p>In October,\u00a0<a class=\"\" href=\"https:\/\/valorinternational.globo.com\/business\/news\/2024\/10\/04\/novo-nordisk-announces-r864m-investment-in-factory-in-minas-gerais.ghtml\">Novo Nordisk disclosed an investment of R$864.2 million for insulin production at the same Montes Claros facility<\/a>. The plant produces approximately 12% of global insulin consumption and is the sole producer of enzymes for the Danish pharmaceutical company.<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>While the company did not disclose current production numbers, it expects to triple enzyme production. The investment is funded with the company\u2019s own capital.<\/li>\n<\/ul>\n\n\n\n<p>Construction is slated to begin in January 2025, with sanitary adjustments expected to start a year later, in January 2026. Novo Nordisk anticipates the new annex will be operational by January 2027.<\/p>\n\n\n\n<p>Reinaldo Costa, corporate vice president of the Novo Nordisk plant, stated that the satisfactory performance indicators of the Montes Claros facility justify the investments in Brazil.<\/p>\n\n\n\n<p>\u201cThis investment is crucial as it will allow us to triple our production capacity for enzymes enteropeptidase and ALP. All semaglutide production requires enzymes supplied by the country, and the plant is the sole enzyme supplier to Novo,\u201d he stated.<\/p>\n\n\n\n<p>The chemical input removes disposable parts from semaglutide, the active ingredient in Ozempic, thereby increasing the efficiency of the active pharmaceutical ingredient (API).<\/p>\n\n\n\n<p>In 2026, the patent for Ozempic is set to expire. The company claims it is unaware of how other pharmaceutical firms will produce potential generic medications, and for this reason, there are no expectations of selling the enzymes to competitors.<\/p>\n\n\n\n<p>\u201cThe expertise we already have here in enzyme production enabled us to attract this investment, with a very good capacity that meets Novo\u2019s market needs. Efficiency, high productivity, and competitive costs are why this investment is being made in Brazil. We are part of a global production strategy, and the Montes Claros site is highly strategic,\u201d Mr. Costa said.<\/p>\n\n\n\n<p>The Montes Claros complex, inaugurated in 2007, employs 1,800 workers and generates approximately 30,000 indirect jobs throughout the production chain, according to the company. The construction of the annex is expected to create 40 direct jobs and 400 indirect jobs.<\/p>\n\n\n\n<p>*By\u00a0Matheus Oliveira<\/p>\n\n\n\n<p>Source: Valor International<\/p>\n\n\n\n<figure class=\"wp-block-embed\"><div class=\"wp-block-embed__wrapper\">\nhttps:\/\/valorinternational.globo.com\/\n<\/div><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Expansion aims to boost production of enzymes essential for manufacturing Ozempic and Wegovy, medications used to treat diabetes and obesity 12\/10\/2024 Danish pharmaceutical company Novo Nordisk announced on Monday (9) an additional investment of R$500 million in Brazil. The funds will be used to construct a new annex at the company\u2019s plant in Montes Claros, [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[8106],"tags":[25703,25702],"class_list":["post-92166","post","type-post","status-publish","format-standard","hentry","category-murray-news","tag-enzyme-production-in-brazil","tag-novo-nordisk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novo Nordisk to expand enzyme production in Brazil - Murray Advogados<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk to expand enzyme production in Brazil - Murray Advogados\" \/>\n<meta property=\"og:description\" content=\"Expansion aims to boost production of enzymes essential for manufacturing Ozempic and Wegovy, medications used to treat diabetes and obesity 12\/10\/2024 Danish pharmaceutical company Novo Nordisk announced on Monday (9) an additional investment of R$500 million in Brazil. The funds will be used to construct a new annex at the company\u2019s plant in Montes Claros, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\" \/>\n<meta property=\"og:site_name\" content=\"Murray Advogados\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T18:43:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T18:43:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\" \/>\n<meta name=\"author\" content=\"Gelcy Bueno\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Gelcy Bueno\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\"},\"author\":{\"name\":\"Gelcy Bueno\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"headline\":\"Novo Nordisk to expand enzyme production in Brazil\",\"datePublished\":\"2024-12-10T18:43:08+00:00\",\"dateModified\":\"2024-12-10T18:43:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\"},\"wordCount\":457,\"image\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\",\"keywords\":[\"enzyme production in Brazil\",\"Novo Nordisk\"],\"articleSection\":[\"Murray News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\",\"url\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\",\"name\":\"Novo Nordisk to expand enzyme production in Brazil - Murray Advogados\",\"isPartOf\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\",\"datePublished\":\"2024-12-10T18:43:08+00:00\",\"dateModified\":\"2024-12-10T18:43:11+00:00\",\"author\":{\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\"},\"breadcrumb\":{\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage\",\"url\":\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\",\"contentUrl\":\"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\/\/murray.adv.br\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk to expand enzyme production in Brazil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/murray.adv.br\/en\/#website\",\"url\":\"https:\/\/murray.adv.br\/en\/\",\"name\":\"Murray Advogados\",\"description\":\"PLG International Lawyers\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/murray.adv.br\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e\",\"name\":\"Gelcy Bueno\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g\",\"caption\":\"Gelcy Bueno\"},\"url\":\"https:\/\/murray.adv.br\/en\/author\/news\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo Nordisk to expand enzyme production in Brazil - Murray Advogados","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk to expand enzyme production in Brazil - Murray Advogados","og_description":"Expansion aims to boost production of enzymes essential for manufacturing Ozempic and Wegovy, medications used to treat diabetes and obesity 12\/10\/2024 Danish pharmaceutical company Novo Nordisk announced on Monday (9) an additional investment of R$500 million in Brazil. The funds will be used to construct a new annex at the company\u2019s plant in Montes Claros, [&hellip;]","og_url":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/","og_site_name":"Murray Advogados","article_published_time":"2024-12-10T18:43:08+00:00","article_modified_time":"2024-12-10T18:43:11+00:00","og_image":[{"url":"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg","type":"","width":"","height":""}],"author":"Gelcy Bueno","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Gelcy Bueno","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#article","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/"},"author":{"name":"Gelcy Bueno","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"headline":"Novo Nordisk to expand enzyme production in Brazil","datePublished":"2024-12-10T18:43:08+00:00","dateModified":"2024-12-10T18:43:11+00:00","mainEntityOfPage":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/"},"wordCount":457,"image":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage"},"thumbnailUrl":"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg","keywords":["enzyme production in Brazil","Novo Nordisk"],"articleSection":["Murray News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/","url":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/","name":"Novo Nordisk to expand enzyme production in Brazil - Murray Advogados","isPartOf":{"@id":"https:\/\/murray.adv.br\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage"},"image":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage"},"thumbnailUrl":"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg","datePublished":"2024-12-10T18:43:08+00:00","dateModified":"2024-12-10T18:43:11+00:00","author":{"@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e"},"breadcrumb":{"@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#primaryimage","url":"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg","contentUrl":"https:\/\/s2-valorinternational.glbimg.com\/TQoo_oxcY0tH43sgtHr4NYDZW3E=\/0x0:2290x1235\/984x0\/smart\/filters:strip_icc()\/i.s3.glbimg.com\/v1\/AUTH_63b422c2caee4269b8b34177e8876b93\/internal_photos\/bs\/2024\/e\/n\/7QBhQGQTqmz0Bm0W8AVQ\/site-20moc-202-20-281-29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/murray.adv.br\/en\/novo-nordisk-to-expand-enzyme-production-in-brazil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/murray.adv.br\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk to expand enzyme production in Brazil"}]},{"@type":"WebSite","@id":"https:\/\/murray.adv.br\/en\/#website","url":"https:\/\/murray.adv.br\/en\/","name":"Murray Advogados","description":"PLG International Lawyers","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/murray.adv.br\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/dd0d0bea46c2436124555d18c1a0d52e","name":"Gelcy Bueno","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/murray.adv.br\/en\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1ef2acfe966d6deacdeccd2a24ea89192c41fd05fc60e57b79021358a47f5641?s=96&d=mm&r=g","caption":"Gelcy Bueno"},"url":"https:\/\/murray.adv.br\/en\/author\/news\/"}]}},"_links":{"self":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/92166","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/comments?post=92166"}],"version-history":[{"count":1,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/92166\/revisions"}],"predecessor-version":[{"id":92167,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/posts\/92166\/revisions\/92167"}],"wp:attachment":[{"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/media?parent=92166"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/categories?post=92166"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/murray.adv.br\/en\/wp-json\/wp\/v2\/tags?post=92166"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}